

Lignan Derivatives from *Fraxinus rhynchophylla* and Inhibitory Activity on Pancreatic Lipase

Jong Hoon Ahn, Eunjin Shin, Qing Liu, Seon Beom Kim, Kyeong-Mi Choi, Hwan-Soo Yoo, Bang Yeon Hwang, and Mi Kyeong Lee*

College of Pharmacy, Chungbuk National University, Cheongju 361-763, Korea

Abstract – Pancreatic lipase digests dietary fats by hydrolysis, which is a key enzyme for lipid absorption. Therefore, reduction of fat absorption by the inhibition of pancreatic lipase is suggested to be a therapeutic strategy for obesity. We previously reported coumarins and secoiridoids of *Fraxinus rhynchophylla* as inhibitory constituents on adipocyte differentiation. Further investigation on *F. rhynchophylla* led to the isolation of lignan derivatives such as lignans (**1** - **10**), sesquilignans (**11** - **14**) and coumarinolignans (**15** - **17**). Among them, coumarinolignans and sesquilignans were first reported from *Fraxinus* species. Among the constituents isolated, sesquilignans showed the significant inhibition on pancreatic lipase, whereas lignans and coumarinolignans exerted weak effects.

Keywords – *Fraxinus rhynchophylla*, pancreatic lipase, sesquilignan, coumarinolignan, obesity

Introduction

Obesity is becoming one of the serious threats to global health in modern days. Obesity is no longer considered only a cosmetic problem but associated with several pathological disorders, including diabetes, hypertension, atherosclerosis and cancer (Kopelman, 2000). Due to these serious problems in health, World Health Organization (WHO) has prompted to promote strategies to prevent and control its progress (Brug and Crawford, 2009). Obesity arises from chronic imbalance between energy intake and energy expenditure, which results in excessive total fat mass. Energy intake starts from fat absorption through digestion of fat into monoglycerides and fatty acids, catalyzed by lipases. Absorbed fat is further accumulated into adipose tissue, which is called adipocyte differentiation. Therefore, inhibition of fat absorption and/or fat accumulation by the disturbance of lipase and adipocyte differentiation is suggested to be important therapeutics in obesity.

Pancreatic lipase, a key enzyme for lipid absorption, is responsible for the hydrolysis of 50-70% of total dietary fats (Birari and Bhutani, 2007). Reduction of fat absorption by the inhibition of pancreatic lipase is known to be

beneficial for the regulation of obesity (Yun, 2010). Orlistat, a specific pancreatic lipase inhibitor, has been clinically used for the prevention of obesity (Ballinger and Peikin, 2002). Recently, there is a growing interest in searching for pancreatic lipase inhibitors from natural products with lower adverse effects. Several natural products including saponins and flavonoids have been reported to have pancreatic lipase inhibitory activity (Xu *et al.*, 2005; Nakai *et al.*, 2005; Li *et al.*, 2007; Lee *et al.*, 2010).

Fraxinus rhynchophylla Dence (Oleaceae) is a traditional medicinal plant widely used in Asia. The stem barks of *F. rhynchophylla* have been used as an antibacterial, analgesic and anti-inflammatory agent. In addition, diuretic, anti-coagulant, antiallergic effects have been reported by pharmacological studies (Kim *et al.*, 1999; Bae 1999). We previously investigated the inhibitory activity of *F. rhynchophylla* on adipocyte differentiation using 3T3-L1 preadipocyte cell lines. Our previous study suggests that coumarins and secoiridoids of *F. rhynchophylla* are effective in inhibition of adipocyte differentiation (Shin *et al.*, 2010; Choi *et al.*, 2011). In a continuation of our research on *F. rhynchophylla*, further seventeen lignan derivatives were isolated and the structures were identified. In the present, we report the isolation of constituents from *F. rhynchophylla* and inhibitory effects on pancreatic lipase activity.

*Author for correspondence

Tel: +82-43-261-2818; E-mail: mklee@chungbuk.ac.kr

Experimental

General experimental procedures – NMR spectra were recorded on a Bruker DRX 500 MHz NMR spectrometer using CDCl₃, CD₃OD and DMSO-*d*₆ as solvents. EI-mass spectra were obtained on VG Autospec Ultima (Micromass, Manchester, UK) mass spectrometers. Semi-preparative HPLC was performed using a Waters HPLC system equipped with Waters 600 Q-pumps, a 996 photodiode array detector, and Waters Empower software using Gemini-NX ODS-column (5 μm, 10 × 150 mm). Silica gel (70 - 230 mesh, Merck, Germany) and Sephadex LH-20 (25 - 100 μm, Amersham Biosciences, Sweden) were used for open column chromatography (CC). Thin-layer chromatography (TLC) was performed on a precoated silica gel 60 F₂₅₄ (0.25 mm, Merck, Germany). All other chemicals and reagents were analytical grade.

Plant material – The stem barks of *F. rhynchophylla* were purchased from local herbal Market, Chungbuk, Korea in December 2008. They were identified by the herbarium of College of Pharmacy at Chungbuk National University, where a voucher specimen was deposited (CBNU200812-FR).

Extraction and isolation – The stem barks of *F. rhynchophylla* (6.0 kg) were extracted 3 times with 80% MeOH, which yielded the methanolic extract (595 g). The methanolic extract was then suspended in H₂O and partitioned successively with *n*-hexane, CHCl₃, EtOAc and *n*-BuOH. The CHCl₃ fraction (45.2 g) was subjected to column chromatography over Sephadex LH-20 with MeOH to give 11 fractions (C1-C11). Compounds **15** and **16** were obtained by recrystallization of C5 and C7, respectively, using MeOH. C6 was further subjected to CC over Sephadex LH-20 eluted with CH₂Cl₂:MeOH to give 3 subfraction (C61-C63). Compound **8** was isolated from C61 by semipreparative HPLC. Compounds **1**, **6**, **11**, **12** and **17** were isolated from C62 by semipreparative HPLC. Compound **2** was isolated from C9 by semipreparative HPLC. Compounds **7**, **9**, **13** and **14** were isolated from C10 by semipreparative HPLC. The EtOAc fraction (50 g) was subjected to silica gel column chromatography with a mixture of CHCl₃-MeOH to give 7 fractions (E1-E7). E6 was further subjected to Sephadex LH-20 column chromatography using MeOH to give 5 subfractions (E61-E65). The *n*-BuOH fraction was subjected to HP-20 column chromatography eluted with the mixture of MeOH and H₂O to give 6 fractions (B1-B6). Compounds **4**, **5** and **10** were isolated from B2, B3 and B4, respectively, by semipreparative HPLC after Sephadex LH-20 column chromatography using MeOH.

The purity of each compound was verified >95% by HPLC.

Assessment of pancreatic lipase activity – Pancreatic lipase inhibitory activity was evaluated using previously reported methods with a minor modification (Nakai *et al.*, 2005; Lee *et al.*, 2010). Briefly, enzyme solution was prepared by the reconstitution of porcine pancreatic lipase (Sigma, St. Louis, MO) in 0.1 M Tris-HCl buffer (pH 8). Then, test sample was mixed with enzyme buffer, and incubated for 15 min at 37 °C. After incubation, 10 mM *p*-nitrophenylbutyrate (*p*-NPB) was added and the enzyme reaction was allowed to proceed for 15 min at 37 °C. Pancreatic lipase activity was determined by measuring the hydrolysis of *p*-NPB to *p*-nitrophenol at 405 nm using a microplatereader. Lipase activity was expressed as the percentage decrease in the OD when incubated with the test compounds. Orlistat (Sigma, St. Louis, MO) was used as a positive control.

Statistical analysis – The evaluation of statistical significance was determined by the Student's *t*-test with a value of *p* < 0.05 or less considered to be statistically significant.

Results and discussion

The methanolic extract was further fractionated into *n*-hexane, CHCl₃, EtOAc and *n*-BuOH fractions. Among them, CHCl₃ and EtOAc fraction showed significant inhibitory activity on pancreatic lipase at the concentration of 100 μg/ml and 300 μg/ml (Table 1). Further fractionation and separation of CHCl₃, EtOAc and *n*-BuOH fraction by several chromatographic methods yielded seventeen lignan derivatives such as lignans (**1** - **10**),

Table 1. Effects of total methanolic extract and each fraction of *F. rhynchophylla* on pancreatic lipase activity

Fraction	Pancreatic lipase activity (%) ^{a)}	
	100 μg/ml	300 μg/ml
Control	100.0 ± 3.1	100.0 ± 3.1
Total extract	90.7 ± 5.0	74.0 ± 4.9
<i>n</i> -hexane fraction	96.7 ± 5.4	77.0 ± 5.3
CHCl ₃ fraction	78.2 ± 4.3*	68.0 ± 5.2*
EtOAc fraction	73.3 ± 5.1*	53.9 ± 7.1**
<i>n</i> -BuOH fraction	87.7 ± 4.9	77.5 ± 6.1
Aqueous fraction	100.4 ± 3.5	87.7 ± 6.5

^{a)} Relative pancreatic lipase activity (%) was calculated as (activity of compound with substrate – negative control of compound without substrate) / (activity without compound with substrate – negative control of without compound and substrate) × 100.

* *p* < 0.05, ** *p* < 0.01 compared with differentiated control.




Fig. 1. Chemical constituents isolated from the stem barks of *F. rhynchophylla*.

sesquilignans (**11 - 14**) and coumarinolignans (**15 - 17**). All the constituents were identified as pinosresinol (**1**), 8-hydroxypinosresinol (**2**), pinosresinol 4-*O*- β -D-glucoside (**3**), syringaresinol 4-*O*- β -D-glucoside (**4**), syringaresinol 4, 4'-*O*- β -D-diglucoside (**5**), epipinosresinol (**6**), lariciresinol (**7**), olivil (**8**), dihydrodehydrodiconiferyl alcohol (**9**), balanophonin 4-*O*- β -D-glucoside (**10**), ficusesquilignan (**11**), hedytol C (**12**), acemikol (**13**), dihydrobuddlenol B (**14**), cleomiscosin A (**15**), cleomiscosin C (**16**) and cleomiscosin B (**17**) (Fig. 1), by the direct comparison of their physicochemical and spectroscopic data with those of previously reported (Achenbach *et al.*, 1983; Yoshinari *et al.*, 1990; Li and Kuo, 2000; Schumacher *et al.*, 2002; Morikawa *et al.*, 2003; Xie *et al.*, 2003; Ouyang

et al., 2007; Ranjan and Sahai, 2009). To our best knowledge, compounds with the skeletons of sesquilignans (**11-14**) and coumarinolignans (**15-17**) are first reported from *Fraxinus* species. In addition, compounds **7-10** were first reported from this plant.

All isolates were evaluated for their inhibitory effects on pancreatic lipase activity using porcine pancreatic lipase *in vitro*. Among the compounds isolated, two sesquilignan (**13 - 14**) also showed significant inhibition, followed by other sesquilignans (**11 - 12**) and lignan (**9**). However, other lignans (**1 - 8, 10**) and coumarinolignans (**15 - 17**) exerted little effects on pancreatic lipase activity at the concentration tested in our study.

Natural products contain diverse constituents, which




Fig. 2. Effect of compounds **1-17** from *F. rhynchophylla* on pancreatic lipase activity. Pancreatic lipase activity was measured using 4-nitrophenylbutyrate as a substrate. Relative lipase activity (%) was calculated as (activity of compound with substrate – negative control of compound without substrate) / (activity without compound and with substrate – negative control without compound and substrate) × 100. Results are expressed as the mean ± S.D. of three independent experiments, each performed using triplicate wells. *p < 0.05, **p < 0.01 compared with control.

allow multiple activities. Synergic action of these mechanisms is preferred for the most effective way to treatment of obesity. Therapeutics for obesity can be developed by various ways such as lipase inhibition, suppression on food intake, stimulation of energy expenditure, inhibition on adipocyte differentiation and regulation on lipid metabolism (Yun, 2010). We previously demonstrated the inhibitory activity of coumarins and secoiridoids of *F. rhynchophylla* on adipocyte differentiation (Shin *et al.*, 2010; Choi *et al.*, 2011). Our present study shows the inhibitory activity of sesquilignans of *F. rhynchophylla* on pancreatic lipase. Therefore, we suggest that *F. rhynchophylla*, which contains coumarins, secoiridoids and sesquilignans, might be beneficial to the treatment of obesity by the combinatorial action of these constituents.

Acknowledgement

This work was supported by Basic Science Research Program (2011-0003494) through the National Research Foundation of Korea.

References

Achenbach, H., Waibel, R., and Addae-Mensah I., Lignans and other constituents from *Carissa edulis*. *Phytochemistry* **22**, 749-753 (1983).
 Bae, K.H., *The Medicinal Plants of Korea*, Kyo-Hak Publishing Co., Seoul, Korea, 400 (1999).

Ballinger, A. and Peikin, S.R., Orlistat: its current status as an anti-obesity drug. *Eur. J. Pharmacol.* **440**, 109-117 (2002).
 Birari, R.B. and Bhutani, K.K., Pancreatic lipase inhibitors from natural sources: unexplored potential. *Drug Discov. Today* **12**, 879-889 (2007).
 Brug, J. and Crawford, D., The obesity pandemic. Is it bad or worse? *Eur. J. Public Health* **19**, 570-571 (2009).
 Choi, K.M., Shin, E., Liu, Q., Yoo, H.S., Kim, Y.C., Sung, S.H., Hwang, B.Y., Lee, and M.K., Hydroxyframoside B, a secoiridoid from *Fraxinus rhynchophylla*, inhibits adipocyte differentiation in 3T3-L1 cells. *Planta Med.* **77**, 1020-1023 (2011).
 Hill, J.O., Hauptman, J., Anderson, J.W., Fujioka, K., O'Neil, P.M., Smith, D.K., Zavoral, J.H., Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. *Am. J. Clin. Nutr.* **69**, 1108-1116 (1999).
 Kim, N.Y., Pae, H.O., Ko, Y.S., Yoo, J.C., Choi, B.M., Jun, C.D., Chung, H.T., Inagaki, M., Kiguchi, R., and Kim, Y.C., In vitro inducible nitric oxide synthesis inhibitory active constituents from *Fraxinus rhynchophylla*. *Planta Med.* **65**, 656-658 (1999).
 Kopelman, P.G., Obesity as a medical problem. *Nature* **404**, 635-643 (2000).
 Lee, E.M., Lee, S.S., Chung, B.Y., Cho, J.Y., Lee, I.C., Ahn, S.R., Jang, S.J., and Kim, T.H., Pancreatic lipase inhibition by C-glycosidic flavones isolated from *Erechiochloaaphiuroides*. *Molecules* **15**, 8251-8259 (2010).
 Li, Y.C. and Kuo, Y.H., Four new compounds, fical, ficalsesquilignan A, B, and ficalolideacetate from the heartwood of *Fucus microcarpa*. *Chem. Pharm. Bull.* **48**, 1862-1865 (2000).
 Li, F., Li, W., Fu, H., Zhang, Q., and Koike, K., Pancreatic lipase-inhibiting triterpenoid saponins from fruits of *Acanthopanax senticosus*. *Chem. Pharm. Bull.* **55**, 1087-1089 (2007).
 Morikawa, T., Tao, J., Ueda, K., Matsuda, H., and Yoshikawa, M., Structure of new aromatic constituents and inhibitors of degranulation in RBL-3H3 cells from a Japanese folk medicine, the stem bark of *Acer nikoense*. *Chem. Pharm. Bull.* **51**, 62-67 (1993).

- Nakai, N., Fukui, Y., Asami, S., Toyoda-Ono, Y., Iwashita, T., Shibata, H., Mitsunaga, T., Hashimoto, F., and Kiso, Y., Inhibitory effects of oolong tea polyphenols on pancreatic lipase *in vitro*. *J. Agric. Food Chem.* **53**, 4593-4598 (2005).
- Ouyang, M.A., Wein, Y.S., Zhang, Z.K., and Kuo, Y.H., Inhibitory activity against tobacco mosaic virus (TMV) replication of pinoresinol and syringaresinol lignans and their glycosides from the root of *Rhus javanica* var. *roxburghiana*. *J. Agric. Food Chem.* **55**, 6460-6465 (2007).
- Ranjan, R. and Sahai, M., Coumarinolignans from the seeds of *Annonasquamosa* Linn. *E-J. Chem.* **6**, 518-522 (2009).
- Schumacher, B., Scholle, S., Holzl, J., Khudeir, N., Hess, S., and Muller, C.E., Lignans isolated from Valerian: Identification and characterization of a new olivil derivative with partial agonistic activity at A1 adenosine receptors. *J. Nat. Prod.* **65**, 1479-1485 (2002).
- Shin, E., Choi, K.M., Yoo, H.S., Lee, C.K., Hwang, B.Y., and Lee, M.K., Inhibitory effects of coumarins from the stem barks of *Fraxinus rhynchophylla* on adipocyte differentiation in 3T3-L1 cells. *Biol. Pharm. Bull.* **33**, 1610-1614 (2010).
- Xie, L.H., Akao, T., Hamasaki, K., Deyama, T., and Hattori, M., Biotransformation of pinoresinol diglucoside to mammalian lignans by human intestinal microflora and isolation of *Enterococcus faecalis* strain PDG-1 responsible of the transformation of pinoresinol to lariciresinol. *Chem. Pharm. Bull.* **51**, 508-515 (2003).
- Xu, B., Han, L., Zheng, Y., Lee, J., and Sung, C., In vitro inhibitory effect of triterpenoidal saponins from *Platycodi Radix* on pancreatic lipase. *Arch. Pharm. Res.* **28**, 180-185 (2005).
- Yoshinari, K., Shimazaki, N., Sashida, Y., and Mimaki, Y., Flavanone xyloside and lignans from *Prunus jamasakura*. *Phytochemistry* **29**, 1675-1678 (1990).
- Yun, J.W., Possible anti-obesity therapeutics from nature. *Phytochemistry* **71**, 1625-1641 (2010).

Received May 2, 2012

Revised May 21, 2012

Accepted May 22, 2012